Literature DB >> 18205092

Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.

C Onofri1, M Losa, E Uhl, G K Stalla, U Renner.   

Abstract

The angiogenic growth factor Vascular Endothelial Growth Factor-C (VEGF-C) and its receptor VEGFR-3 are also known to be implicated in the development of lymphatic vessels. We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections. VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3. Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary. Most of the tumours positive for VEGFR-3 did not show any LYVE-1 positive vessels (18/53), suggesting that at least in these cases, VEGFR-3 is expressed on blood vessels. Nevertheless, we observed a significant association between low expression of VEGFR-3 and low lymphatic vessel number, suggesting that VEGFR-3 might be involved in the starting of DE NOVO lymphangiogenesis in this tumour type. Moreover, tumours bearing lymphatic vessels showed the tendency to shift towards a more aggressive behaviour (high tumour grade and high PI). In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205092     DOI: 10.1055/s-2007-992120

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  2 in total

1.  Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma.

Authors:  Kenta Koketsu; Daizo Yoshida; Kyongsong Kim; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; Akio Morita
Journal:  Int J Endocrinol       Date:  2015-03-05       Impact factor: 3.257

2.  [Inhibitory effect of endostar on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells].

Authors:  Liqun Shang; Jie Zhao; Wei Wang; Wang Xiao; Jun Li; Xuechang Li; Weian Song; Junqiang Liu; Feng Wen; Caiying Yue
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.